Dashboard

MRNA

Moderna, Inc.

NasdaqGS · USD · Stock

$221.72

+18.26 (+8.97%)

past month

Closed
Market cap
$88.52B
Volume
9M
52 weeks
$22.28 – $254

About

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.

Moderna, Inc. (MRNA) is a healthcare company listed on Nasdaq, traded in USD. Over the past year it moved between $22.28 and $254.48.

  • Healthcare
  • Biotechnology
  • Cambridge, United States
  • 4.7K employees
  • Led by Stéphane Bancel M.B.A.

Coming up

  • Earnings

    Next report

    Expected EPS -$1.35 · revenue $891.31M

Financials

Revenue, last 12 months

$2.23B+2.10%

2022202320242025

Earnings

Beat the estimate

4 of 4 quarters

  • Q3 2025

    +76.60%

  • Q4 2025

    +18.88%

  • Q1 2026

    +12.37%

  • Q2 2026

    +4.33%

Earnings per share, last 12 months -$7.98

Analysts

19 analysts say

Hold

12-month target$138.37-37.59%

Ownership

Institutions
80.49%
Insiders
7.36%

Latest insider trade Oct 5, 2026, MOCK JAMES M

Prices from Yahoo Finance, may be delayed